A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue

Janet A. Gilbertson, Jason D. Theis, Julie A. Vrana, Helen Lachmann, Ashutosh Wechalekar, Carol Whelan, Philip N. Hawkins, Ahmet Dogan, Julian D. Gillmore

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Amyloidosis is caused by deposition in tissues of abnormal protein in a characteristic fibrillar form. There are many types of amyloidosis, classified according to the soluble protein precursor from which the amyloid fibrils are derived. Accurate identification of amyloid type is critical in every case since therapy for systemic amyloidosis is type specific. In ∼20-25% cases, however, immunohistochemistry (IHC) fails to prove the amyloid type and further tests are required. Laser microdissection and mass spectrometry (LDMS) is a powerful tool for identifying proteins from formalin-fixed paraffin-embedded tissues. We undertook a blinded comparison of IHC, performed at the UK National Amyloidosis Centre, and LDMS, performed at the Mayo Clinic, in 142 consecutive biopsy specimens from 38 different tissue types. There was 100% concordance between positive IHC and LDMS, and the latter increased diagnostic accuracy from 76% to 94%. LDMS in expert hands is a valuable tool for amyloid diagnosis.

Original languageEnglish (US)
Pages (from-to)314-317
Number of pages4
JournalJournal of clinical pathology
Volume68
Issue number4
DOIs
StatePublished - Apr 1 2015

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue'. Together they form a unique fingerprint.

  • Cite this

    Gilbertson, J. A., Theis, J. D., Vrana, J. A., Lachmann, H., Wechalekar, A., Whelan, C., Hawkins, P. N., Dogan, A., & Gillmore, J. D. (2015). A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Journal of clinical pathology, 68(4), 314-317. https://doi.org/10.1136/jclinpath-2014-202722